Citius Oncology grants medical chief 400K stock options
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Citius Oncology, Inc. Chief Medical Officer Myron Czuczman received 400,000 stock options covering 400,000 common shares on November 9, 2026, with an exercise price of $0.5495 per share. The options vest one-third on each of the first, second and third anniversaries, subject to his continuous service to the company or a related entity on each vesting date.
Czuczman also reported direct ownership of 825,000 common shares and existing options covering 400,000 shares at a $1.07 exercise price, expiring December 12, 2034, and 1,400,000 shares at a $2.15 exercise price, expiring July 5, 2033.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F1 | 400,000 | $0.00 | $0.00 |
| Holding | Stock Option (Right to Buy) F2 | -- | -- | -- |
| Holding | Stock Option (Right to Buy) F3 | -- | -- | -- |
| Holding | Common Stock | -- | -- | -- |
Footnotes (3)
- F1. These options were granted on November 9, 2026. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date.
- F2. These options were granted on December 12, 2024. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the grant date, subject to the Reporting Person's Continuous Service to the Company or a Related Entity (as defined in the award agreement) as of the applicable vesting date.
- F3. These options vest over three years, beginning July 5, 2023, with 1/36th every month for the first year, and the 1/3 each on the second and third anniversary of the July 5, 2023, subject to the Reporting Person's Continuous Service to the Company or a Related Entity (as defined in the award agreement) as of the applicable vesting date.
Key Figures
Key Terms
Stock Option (Right to Buy) financial
exercise price financial
vest financial
Continuous Service technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What option award did CTOR’s chief medical officer receive?
AI-generated analysis. How Rhea-AI works. Not financial advice.